CAMBRIA-2
Clinical Trial Program
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2-Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Phase III
Status
Initiating
Tumour subtype:
HR+ breast cancer
Scenario
Adjuvant
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Dr. Sibylle Loibl (GBG Forschungs
GmBH, Hessen)
Dr. Sara Tolaney (Dana-Farber Cancer Institute, Boston)
Yeon Hee Park ( Samsung Medical Center, Seul)
Michael Gnant (Austria Breast and Colorectal Cancer Study Group, Viena)
Sites
HOSPITAL CLINIC DE BARCELONA, HOSPITAL DE FUENLABRADA, HOSPITAL DE LEÓN, HOSPITAL DE SANT JOAN DESPI MOISES BROGGI, HOSPITAL FUNDACIÓN JIMÉNEZ DÍAZ, HOSPITAL RAMON Y CAJAL, HOSPITAL SON ESPASES, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO DE CANARIAS, HOSPITAL UNIVERSITARIO MADRID SANCHINARRO (CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (CIOCC)), HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA, HOSPITAL UNIVERSITARIO VIRGEN DE LA MACARENA, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, ICO BADALONA, HOSPITAL DEL MAR
